Dual-centre, double-blind, randomised trial of lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B

R. Giacchino; J. Main; A. Timitilli; G. Giambartolomei; F. Facco; C. Cirillo; M. R. Jacyna; M. G. Brook; F. Callea; P. Kariayannis; A. Terragna; H. C. Thomas

Dual-centre, double-blind, randomised trial of lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B

R. Giacchino, J. Main, A. Timitilli, G. Giambartolomei, F. Facco, C. Cirillo, M. R. Jacyna, M. G. Brook, F. Callea, P. Kariayannis, A. Terragna, H. C. Thomas

Research output: Contribution to journal › Article › peer-review

Abstract

Thirty-five children with chronic HBV infection, HBV-DNA and eAg serum positivity, and HBcAg in liver tissue were treated with lymphoblastoid human interferon alpha with (16 cases) or without (19 cases) prednisolone pretreatment. The patients were double-blind randomized to receive steroid or placebo for 4 weeks, followed after 2 weeks by 5 or 10 MU/m² interferon for 12 weeks. The e anti-e seroconversion rate reached 48%, which is much higher than the spontaneous seroconversion rate. The influence of 'prednisolone priming' was not statistically significant. HBeAg clearance was similar in both groups (44% after prednisolone/interferon and 53% after interferon alone). The response to either treatment did not correlate with the pretreatment serum transaminase, HBV-DNA or degree of histological activity. Interferon was well tolerated, the side effects being less severe than in adults, and never led to suspension of the treatment.

Original language	English
Pages (from-to)	143-148
Number of pages	6
Journal	Liver
Volume	15
Issue number	3
Publication status	Published - 1995

Keywords

Children
HBV
Interferon alpha
Steroid

ASJC Scopus subject areas

Hepatology

Fingerprint Dive into the research topics of 'Dual-centre, double-blind, randomised trial of lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B'. Together they form a unique fingerprint.

Cite this

Dual-centre, double-blind, randomised trial of lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B. / Giacchino, R.; Main, J.; Timitilli, A.; Giambartolomei, G.; Facco, F.; Cirillo, C.; Jacyna, M. R.; Brook, M. G.; Callea, F.; Kariayannis, P.; Terragna, A.; Thomas, H. C.

In: Liver, Vol. 15, No. 3, 1995, p. 143-148.

Research output: Contribution to journal › Article › peer-review

Giacchino, R. ; Main, J. ; Timitilli, A. ; Giambartolomei, G. ; Facco, F. ; Cirillo, C. ; Jacyna, M. R. ; Brook, M. G. ; Callea, F. ; Kariayannis, P. ; Terragna, A. ; Thomas, H. C. / Dual-centre, double-blind, randomised trial of lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B. In: Liver. 1995 ; Vol. 15, No. 3. pp. 143-148.

@article{042112adf9a146b48606d3d30398fb64,

title = "Dual-centre, double-blind, randomised trial of lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B",

abstract = "Thirty-five children with chronic HBV infection, HBV-DNA and eAg serum positivity, and HBcAg in liver tissue were treated with lymphoblastoid human interferon alpha with (16 cases) or without (19 cases) prednisolone pretreatment. The patients were double-blind randomized to receive steroid or placebo for 4 weeks, followed after 2 weeks by 5 or 10 MU/m2 interferon for 12 weeks. The e anti-e seroconversion rate reached 48%, which is much higher than the spontaneous seroconversion rate. The influence of 'prednisolone priming' was not statistically significant. HBeAg clearance was similar in both groups (44% after prednisolone/interferon and 53% after interferon alone). The response to either treatment did not correlate with the pretreatment serum transaminase, HBV-DNA or degree of histological activity. Interferon was well tolerated, the side effects being less severe than in adults, and never led to suspension of the treatment.",

keywords = "Children, HBV, Interferon alpha, Steroid",

author = "R. Giacchino and J. Main and A. Timitilli and G. Giambartolomei and F. Facco and C. Cirillo and Jacyna, {M. R.} and Brook, {M. G.} and F. Callea and P. Kariayannis and A. Terragna and Thomas, {H. C.}",

year = "1995",

language = "English",

volume = "15",

pages = "143--148",

journal = "Liver",

issn = "0106-9543",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Dual-centre, double-blind, randomised trial of lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B

AU - Giacchino, R.

AU - Main, J.

AU - Timitilli, A.

AU - Giambartolomei, G.

AU - Facco, F.

AU - Cirillo, C.

AU - Jacyna, M. R.

AU - Brook, M. G.

AU - Callea, F.

AU - Kariayannis, P.

AU - Terragna, A.

AU - Thomas, H. C.

PY - 1995

Y1 - 1995

N2 - Thirty-five children with chronic HBV infection, HBV-DNA and eAg serum positivity, and HBcAg in liver tissue were treated with lymphoblastoid human interferon alpha with (16 cases) or without (19 cases) prednisolone pretreatment. The patients were double-blind randomized to receive steroid or placebo for 4 weeks, followed after 2 weeks by 5 or 10 MU/m2 interferon for 12 weeks. The e anti-e seroconversion rate reached 48%, which is much higher than the spontaneous seroconversion rate. The influence of 'prednisolone priming' was not statistically significant. HBeAg clearance was similar in both groups (44% after prednisolone/interferon and 53% after interferon alone). The response to either treatment did not correlate with the pretreatment serum transaminase, HBV-DNA or degree of histological activity. Interferon was well tolerated, the side effects being less severe than in adults, and never led to suspension of the treatment.

AB - Thirty-five children with chronic HBV infection, HBV-DNA and eAg serum positivity, and HBcAg in liver tissue were treated with lymphoblastoid human interferon alpha with (16 cases) or without (19 cases) prednisolone pretreatment. The patients were double-blind randomized to receive steroid or placebo for 4 weeks, followed after 2 weeks by 5 or 10 MU/m2 interferon for 12 weeks. The e anti-e seroconversion rate reached 48%, which is much higher than the spontaneous seroconversion rate. The influence of 'prednisolone priming' was not statistically significant. HBeAg clearance was similar in both groups (44% after prednisolone/interferon and 53% after interferon alone). The response to either treatment did not correlate with the pretreatment serum transaminase, HBV-DNA or degree of histological activity. Interferon was well tolerated, the side effects being less severe than in adults, and never led to suspension of the treatment.

KW - Children

KW - HBV

KW - Interferon alpha

KW - Steroid

UR - http://www.scopus.com/inward/record.url?scp=0029028497&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029028497&partnerID=8YFLogxK

M3 - Article

C2 - 7674841

AN - SCOPUS:0029028497

VL - 15

SP - 143

EP - 148

JO - Liver

JF - Liver

SN - 0106-9543

IS - 3

ER -

Dual-centre, double-blind, randomised trial of lymphoblastoid interferon alpha with or without steroid pretreatment in children with chronic hepatitis B

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Cite this